Results 191 to 200 of about 16,333 (257)

Oseltamivir drug‐disease modelling in infants with influenza virus infection

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Oseltamivir is a commonly used neuraminidase inhibitor for treatment of influenza infection, but little data exist regarding concentration‐response relationships. Methods Pharmacokinetic (PK) and viral dynamic data from an earlier NIAID Collaborative Antiviral Study Group trial in paediatric patients with influenza from 0–23 months of age
Kun Wang, David W. Kimberlin, Richard J. Whitley, Edward P. Acosta, For the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group   +4 more
wiley   +1 more source

The Natural History of Hepatitis C Virus Infection and Disease in the Era of Curative Therapy with Direct-Acting Antivirals. [PDF]

Viruses
Brunetto MR, Bonino F.
europepmc   +1 more source

Lost and found in translation: the value of the human imiquimod model

British Journal of Clinical Pharmacology, EarlyView.
Topical imiquimod (IMQ), a Toll‐like receptor (TLR) 7 agonist, induces transient cutaneous inflammation and is widely used in preclinical research as a ‘psoriasis‐like’ mouse model. However, accumulating evidence indicates substantial divergence between IMQ‐driven biology and human plaque psoriasis pathogenesis.
Anouk C. Meijs, Juliette A. van den Noort, Salma Assil, Naomi B. Klarenbeek, Matthijs Moerland, Tessa Niemeyer‐van der Kolk, Robert Rissmann   +6 more
wiley   +1 more source

Iron Metabolism Genes Shape the Course of Liver Fibrosis in Chronic Hepatitis C: From Disease Progression to Reversal After Direct-Acting Antivirals Treatment. [PDF]

Viruses
Ferreira J, Bicho M, Faustino P, Serejo F.   +3 more
europepmc   +1 more source

Do consumers and healthcare professionals report the same adverse event differently? A paired analysis of duplicate vaccine safety reports in Norway

British Journal of Clinical Pharmacology, EarlyView.
Aim This study aimed to compare how Norwegian healthcare professionals (HCPs) and consumers reported the same adverse event (AE) following immunization with vaccines against COVID‐19 during the COVID‐19 pandemic. Specifically, we aimed to compare the extent to which HCPs and consumers reported information relevant for assessing the causal relationship ...
Tommy Emil Dzus, Johaina Sarrage, Hilde Samdal, François Montastruc, Elena Rocca   +4 more
wiley   +1 more source

Long-Term Effects of Direct-Acting Antivirals on Hepatitis C: Trends in Liver Disease-Related Hospitalisations in Italy. [PDF]

J Viral Hepat
Mennini FS, Sciattella P, Simonelli C, Marcellusi A, Rosato S, Kondili LA.   +5 more
europepmc   +1 more source

Current practice and guideline adherence in renal dose adjustment for patients with chronic kidney disease: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed, Ahmed Tehemar, Mohamed Gasimelseed, Ahmed Gharaibeh, Muhammad Abdul Hadi, Kazeem Yusuff, Amani Zidan, Ahmed Awaisu   +7 more
wiley   +1 more source

Long-term Effect of the HCV Elimination With Direct-acting Antivirals on the Progression of Gastroesophageal Varices. [PDF]

In Vivo
Yuri Y, Nishimura T, Ikeda N, Takashima T, Aizawa N, Kimura T, Yoshihara K, Yoshioka R, Kawata S, Kawase Y, Nakano R, Shiomi H, Fukunishi S, Shinzaki S, Enomoto H.   +14 more
europepmc   +1 more source

Pharmacokinetic Assessment of Atazanavir and Favipiravir Following Echinacea Supplementation: A Controlled Herb–Drug Interaction Investigation

Biopharmaceutics &Drug Disposition, EarlyView.
Pharmacokinetic interactions between Echinacea and two antiviral drugs, favipiravir and atazanavir, were assessed in rats. The findings suggest that Echinacea does not significantly affect the pharmacokinetics of favipiravir and atazanavir. These results provide preliminary evidence that concurrent use of Echinacea with these antiviral drugs may be ...
Siva Nageswara Rao Gajula, Jeevan Sai Kallam, Aarika Kanukolanu, Ganesh Korada, Lakshmi Vineela Nalla   +4 more
wiley   +1 more source